Table 2 The number (percentage) of PD-L1 positive lung cancer cases depending on cutoff (≥1% and ≥50%) for a positive test, assay, and histology

From: PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability

 

28-8

22C3

SP142

SP263

28-8A

Positive cases, cutoff ≥1%

 Adenocarcinoma (n=29)

12 (41%)

11 (38%)

6 (21%)

13 (45%)

12 (41%)

 Squamous cell carcinoma (n=23)

8 (35%)

5 (22%)

3 (13%)

10 (43%)

7 (32%)

 All (n=55)

21 (38%)

16 (29%)

9 (16%)

23 (42%)

20 (37%)

Positive cases, cutoff ≥50%

 Adenocarcinoma (n=29)

6 (21%)

6 (21%)

2 (7%)

8 (28%)

7 (24%)

 Squamous cell carcinoma (n=23)

5 (22%)

4 (17%)

1 (4%)

5 (22%)

4 (18%)

 All (n=55)

11 (20%)

10 (18%)

3 (5%)

13 (24%)

11 (20%)

  1. Note: 28-8 pharmDx/Dako, 28-8A Abcam; only 54 of the 55 cases were evaluable on the slide stained with 28-8 from Abcam (one squamous cell carcinoma case missing).
Back to article page